The US Food and Drug Administration (FDA) announced the approval of the first generic version of a daily injectable GLP-1 medicine for people living with Type 2 diabetes, reports HealthDay.

Liraglutide, the generic for Victoza, is similar to semaglutide, the active ingredient in the popular weight-loss drug Ozempic.

The FDA supports the development of generic drugs, such as GLP-1s, by funding research and informing industry through guidance, Dr. Iilun Murphy, director of the FDA’s Office of Generic Drugs, said.

“Generic drugs provide additional treatment options which are generally more affordable for patients,” she said in a statement released Monday. “Today’s approval underscores the FDA’s continued commitment to advancing patient access to safe, effective and high-quality generic drug products.”

Last month, the agency approved the first generic version in this class of medications with the green lighting of a generic version of Byetta (exenatide).